Michael Barbella, Managing Editor11.11.22
GlucoTrack Inc. has hired Mark Tapsak, Ph.D., as vice president of Sensor Technology.
Tapsak brings more than 25 years of experience in the diabetes industry as a medical device research scientist, focused on polymer synthesis, polymer characterization, medical device design and intellectual property. At GlucoTrack, he will lead the R&D program for a novel implantable continuous glucose monitoring system (CGM) for those with Type 1 diabetes.
“Mark and I worked together in the early days of development at DexCom, and I am thrilled to be working with him again”, GlucoTrack President and CEO Paul Goode said. “By bringing together a veteran team with proficiency in the implantable device and glucose sensing space, we are looking to bring life-changing products to market that are designed to prioritize both health and comfort, enabling freedom from the pain and inconvenience currently plaguing patients with diabetes.”
Tapsak joins GlucoTrack from Diabetic Health Inc., a developer of specialty coatings utilized in continuous glucose monitoring sensors and insulin infusion sets, where he served as president. Over his career, Tapsak held senior positions at several diabetes management companies including senior scientist at Dexcom Inc. where he was in charge of sensor electrochemical performance, biointerface design, and membrane technology, and as senior chemist at Medtronic. He has also been a professor of Chemistry and Biochemistry and served as the assistant dean of Science and Technology and as dean of Graduate Programs and Sponsored Research at Bloomsburg University. Tapsak has authored dozens of industry publications with thousands of citations and is a named inventor of 68 patents, of which more than 50 are DexCom assigned patents.
Tapsak earned a bachelor's degree of educational studies in chemistry and photographic sciences from St. Cloud State University and his Ph.D. in polymer chemistry from the University of Southern California.
“GlucoTrack’s approach to advancing solutions for the management of diabetes and prediabetes is both unique and innovative,” said Dr. Tapsak. “I consider myself fortunate to be able to join this exceptional team in developing technology that has the potential to help so many.”
GlucoTrack Inc., formerly known as Integrity Applications Inc., designs, develops, and commercializes technologies for people with diabetes and prediabetes. Its initial product, GlucoTrack, is a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices.
Tapsak brings more than 25 years of experience in the diabetes industry as a medical device research scientist, focused on polymer synthesis, polymer characterization, medical device design and intellectual property. At GlucoTrack, he will lead the R&D program for a novel implantable continuous glucose monitoring system (CGM) for those with Type 1 diabetes.
“Mark and I worked together in the early days of development at DexCom, and I am thrilled to be working with him again”, GlucoTrack President and CEO Paul Goode said. “By bringing together a veteran team with proficiency in the implantable device and glucose sensing space, we are looking to bring life-changing products to market that are designed to prioritize both health and comfort, enabling freedom from the pain and inconvenience currently plaguing patients with diabetes.”
Tapsak joins GlucoTrack from Diabetic Health Inc., a developer of specialty coatings utilized in continuous glucose monitoring sensors and insulin infusion sets, where he served as president. Over his career, Tapsak held senior positions at several diabetes management companies including senior scientist at Dexcom Inc. where he was in charge of sensor electrochemical performance, biointerface design, and membrane technology, and as senior chemist at Medtronic. He has also been a professor of Chemistry and Biochemistry and served as the assistant dean of Science and Technology and as dean of Graduate Programs and Sponsored Research at Bloomsburg University. Tapsak has authored dozens of industry publications with thousands of citations and is a named inventor of 68 patents, of which more than 50 are DexCom assigned patents.
Tapsak earned a bachelor's degree of educational studies in chemistry and photographic sciences from St. Cloud State University and his Ph.D. in polymer chemistry from the University of Southern California.
“GlucoTrack’s approach to advancing solutions for the management of diabetes and prediabetes is both unique and innovative,” said Dr. Tapsak. “I consider myself fortunate to be able to join this exceptional team in developing technology that has the potential to help so many.”
GlucoTrack Inc., formerly known as Integrity Applications Inc., designs, develops, and commercializes technologies for people with diabetes and prediabetes. Its initial product, GlucoTrack, is a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices.